Cassava Sciences (NASDAQ:SAVA) was upgraded by analysts at
Wall Street Z
Cassava Sciences (NASDAQ:SAVA) was downgraded by analysts at
Wall Street
Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer’s Disease in the Journal of Prevention of Alzheimer’s Disease
Cassava Sciences (NASDAQ:SAVA) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS